RM-CVS / Coagulation and vascular signalling
B7-33
Also known as: Relaxin B-chain mimetic · Single-chain RXFP1 agonist
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
B7-33 is a minimized relaxin-2 analog designed to favor selected RXFP1 signaling pathways. It is distinct from native two-chain relaxin and from serelaxin.
Evidence position
Cell and animal studies support Grade C. The cited work does not include human exposure.
What the record does not establish
Anti-fibrotic findings in rodents or implanted materials do not establish a human outcome, dose, formulation or commercial-sample identity.
Sources
- 01Design and preclinical characterization of B7-33PubMed
- Shows
- Receptor-signaling work and several rodent fibrosis models
- Does not show
- Preclinical evidence; does not establish human pharmacology or a supplier lot
- 02B7-33 controlled-release coating studyPubMed
- Shows
- In-vitro RXFP1 activity and mouse implant-capsule findings for a defined delivery system
- Does not show
- Device-coating and animal model; not evidence for another route or formulation
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).European journal of pharmacology / 2017 Jul 15PMID 28478069 / DOI 10.1016/j.ejphar.2017.05.005
- Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation.ACS applied materials & interfaces / 2019 Dec 11PMID 31713411 / DOI 10.1021/acsami.9b17859
- B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.Journal of the American Heart Association / 2020 Apr 21PMID 32295457 / DOI 10.1161/JAHA.119.015748
- The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie / 2023 AprPMID 36753958 / DOI 10.1016/j.biopha.2023.114370
- Single chain peptide agonists of relaxin receptors.Molecular and cellular endocrinology / 2019 May 1PMID 30641102 / DOI 10.1016/j.mce.2019.01.008